Traditional Drug Pipeline Monthly Update: November 2022

Critical updates in an ever changing environment

November 18, 2022
This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

See separate articles for pipeline information on specialty drugs.

New Drug Information

  • Rezvoglar® (insulin glargine-aglr): The U.S. Food and Drug Administration (FDA) approved the second interchangeable biosimilar insulin product to Lantus® (insulin glargine), Eli Lilly’s Rezvoglar® (insulin glargine-aglr).1Rezvoglar is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. FDA previously approved Rezvoglar as a biosimilar to Lantus on December 17, 2021.

Generic Drug Information

  • Daliresp® (roflumilast tablet): Multiple manufacturers have launched their generic version of AstraZeneca’s Daliresp for the treatment of chronic obstructive pulmonary disease (COPD). Daliresp generated $260 million in U.S. annual sales in 2021.

+Specialty medication

References

  1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761215

Related news

Perspectives

September 14, 2023

Cheers to 20 years and another amazing Specialty Summit!

The 20th annual Specialty Summit hosted by Prime and Magellan Rx returned to…

Perspectives

September 8, 2023

October 2023 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to…

Perspectives

August 28, 2023

Specialty Drug Pipeline Monthly Update: August 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…